
Opinion|Videos|March 4, 2024
Exploring Therapies for Platinum Sensitive & Platinum-Resistant Ovarian Cancer
A medical expert discusses efficacy of approaches such as carboplatin doublets, checkpoint inhibitors, and PARP inhibitors for patients with platinum sensitive and platinum-resistant ovarian cancer.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
AbbVie Joins Trump Drug Pricing Effort, Pledges $100B in US R&D Investment
2
OpenAI for Healthcare Aims to Streamline Clinical Workflows, Reduce Administrative Burden
3
Medical Debt Emerges as Risk Factor for Housing Instability
4
Rural Hospital Closures Tied to Improved Cancer Surgery Outcomes
5





























































